Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. - Wikidata - awgldk - TriplyDB

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients.

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients.

http://www.wikidata.org/entity/Q37012707

about

Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector.Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma.Immune-Mediated Therapies for Liver Cancer.Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies.Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L.Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy.Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors.Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma.Cancer Immunotherapy Targeted Glypican-3 or Neoantigens.Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.Immunotherapy in Gastrointestinal Cancers.Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations.Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy.Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of immunotherapy Molecular Targets in Hepatocarcinogenesis and Implications for Therapy

P2860

Q33648649-19F639AB-FAED-4E51-9223-C8B1B3C0C98D Q37477273-CAE55016-BF01-48EB-A63C-8127A6587203 Q39144327-95AD54BE-87CC-41B1-A665-3A947FAEE6ED Q39378285-C66CF689-5204-4678-A132-D5E6AD001CC9 Q39458547-3CA98FBE-971D-4671-BD34-195DBAB6DD68 Q40227841-7EDCB315-7896-45C7-B0BD-66EDBE1FC845 Q40279723-11E3E2E2-5067-40D2-BC2D-51E748B173C5 Q45070547-1E19D545-8FD8-4B7A-89ED-C2F260C880A5 Q47118215-A489671E-74E2-4D1E-9A80-D5848B4E0AC5 Q47140396-FB1CACB7-85BB-4F01-95B0-338E9B16EEA7 Q47760070-8488F64C-F68A-4043-95CD-8CDC3A464C84 Q49254379-B146F221-7497-4D92-813E-9C963933AFD9 Q50076590-0D54640D-7D74-48E7-8919-74C0ED966224 Q53183990-19D70B59-D8E5-49C6-976F-7B579DE2A09D Q54963955-A18F4AD3-B067-4FDA-9F27-A5EDB75E5598 Q55709201-D842D85F-CF38-43DA-AED8-10435B0BAE83 Q55715408-1B5CF7CB-899A-487A-B0A5-A74A3F13B24F Q58117622-46E9D617-7531-4A2C-AA95-0271C493E367 Q58784853-CF18FA1D-5A7D-421B-916A-1A41A5669351

P2860

Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients.

http://www.wikidata.org/entity/Q37012707

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 January 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase II study of the GPC3-der ...... tocellular carcinoma patients.

@en

Phase II study of the GPC3-der ...... tocellular carcinoma patients.

@nl

type

label

Phase II study of the GPC3-der ...... tocellular carcinoma patients.

@en

Phase II study of the GPC3-der ...... tocellular carcinoma patients.

@nl

prefLabel

Phase II study of the GPC3-der ...... tocellular carcinoma patients.

@en

Phase II study of the GPC3-der ...... tocellular carcinoma patients.

@nl

P1433

Q37012707-9A4D9672-3368-41A9-8D2E-57D48C84148C

P1476

Q37012707-255321F7-1133-4452-918D-AF7E312669EC

P2093

Q37012707-1E428CB4-3F5A-4A80-98E7-3CD7A38E6C3C

Q37012707-249A9C30-1FED-41CB-B579-B9FF21CF2DD2

Q37012707-29A8CD68-D88D-449F-B4BF-A8622E1EEDBC

Q37012707-2D372489-EE84-43B1-8978-8B9250AC1F66

Q37012707-34FF76CB-8789-4957-B751-70C402296C6A

Q37012707-4B038249-3846-434E-9464-3DED4D400C90

Q37012707-5011CA47-6EAB-4DDF-9C4E-F582AD79D6BB

Q37012707-56387BC7-135D-4AAB-85DD-1D1BC91C9906

Q37012707-5C45BF4C-8F6A-4BAC-BA83-81B2D88268EB

Q37012707-6E7D0548-A0FB-4A00-A69E-B668ED949882

P2860

Q37012707-02CB9572-2FB7-495F-BA26-06D40E9DD11A

Q37012707-2B90AAC8-735C-49BF-8CB8-3B1DB07E39B8

Q37012707-2B94E00C-7AEC-4D6F-9455-980704E8DC9C

Q37012707-32E5F0DF-D67C-4A53-B81C-BFD3E1BAAD5F

Q37012707-343857D8-942F-4D73-8B0F-08FE4BEEE8C0

Q37012707-4022D141-9544-4731-8BAF-ED2D10C79E61

Q37012707-461B0C32-823E-488B-800D-13D438C95456

Q37012707-517668F0-B1E1-4604-A82B-9F2D862FB490

Q37012707-60A5379B-F848-426B-9F81-8D6C44FD849F

Q37012707-61AB7775-EA83-479A-BFCE-7C7742E6764F

P304

Q37012707-EE47F2E7-D797-4FFC-AB7F-60065A514BED

P31

Q37012707-0544ECE8-AA21-4C54-8743-DA3F7EEA76A2

P356

Q37012707-4A59F81C-6AA9-42A7-AE73-3EF84A9AEBEF

P433

Q37012707-8BA23A94-5D13-41AB-986C-63D8B4C23EEA

P478

Q37012707-1C8F994D-116B-45CC-8C03-C19C42B8CF67

P50

Q37012707-0263F10A-791E-4B66-B5E2-7402590319BF

P577

Q37012707-AD9029B4-10CD-4A15-B857-2E40CE2DD946

P698

Q37012707-8DCD7123-55A8-4F48-837D-EC9B2D1E9F38

P932

Q37012707-29171B78-9D0A-42CD-A3C1-BDA038035CFC

P356

2162402X.2015.1129483

P1433

P1476

Phase II study of the GPC3-der ...... tocellular carcinoma patients.

@en

P2093

Daisuke Nobuoka

http://www.w3.org/2001/XMLSchema#string

Itaru Endo

http://www.w3.org/2001/XMLSchema#string

Junji Furuse

http://www.w3.org/2001/XMLSchema#string

Katsuhiko Uesaka

http://www.w3.org/2001/XMLSchema#string

Kazuya Ofuji

http://www.w3.org/2001/XMLSchema#string

Kenji Yamao

http://www.w3.org/2001/XMLSchema#string

Kohei Nakachi

http://www.w3.org/2001/XMLSchema#string

Masafumi Ikeda

http://www.w3.org/2001/XMLSchema#string

Masaru Konishi

http://www.w3.org/2001/XMLSchema#string

Mayuko Yoshimura

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.

A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)

Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide.

Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors.

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.

Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.

Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.

Novel advancements in the management of hepatocellular carcinoma in 2008.

P304

e1129483

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/2162402X.2015.1129483

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27467945

http://www.w3.org/2001/XMLSchema#string

P932

4910752

http://www.w3.org/2001/XMLSchema#string